In the last trading session, 1.04 million Terns Pharmaceuticals Inc (NASDAQ:TERN) shares changed hands as the company’s beta touched -0.38. With the company’s per share price at $7.24 changed hands at -$0.17 or -2.29% during last session, the market valuation stood at $611.35M. TERN’s last price was a discount, traded about -57.46% off its 52-week high of $11.40. The share price had its 52-week low at $3.26, which suggests the last value was 54.97% up since then. When we look at Terns Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 1.24 million shares, with the 3-month average coming to 1.86 million.
Analysts gave the Terns Pharmaceuticals Inc (TERN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.29. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended TERN as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Terns Pharmaceuticals Inc (NASDAQ:TERN) trade information
Instantly TERN was in red as seen at the end of in last trading. With action -4.99%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 11.56%, with the 5-day performance at -4.99% in the red. However, in the 30-day time frame, Terns Pharmaceuticals Inc (NASDAQ:TERN) is -27.74% down. Looking at the short shares, we see there were 4.91 million shares sold at short interest cover period of 1.41 days.
The consensus price target for the stock as assigned by Wall Street analysts is 12, meaning bulls need an upside of 39.67% from its current market value. According to analyst projections, TERN’s forecast low is 7 with 26 as the target high. To hit the forecast high, the stock’s price needs a -259.12% plunge from its current level, while the stock would need to tank 3.31% for it to hit the projected low.
Terns Pharmaceuticals Inc (TERN) estimates and forecasts
Data shows that the Terns Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 50.21% over the past 6 months, a -3.15% in annual growth rate that is considerably lower than the industry average of 17.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -12.40%. The 2024 estimates are for Terns Pharmaceuticals Inc earnings to decrease by -1.36%.
TERN Dividends
Terns Pharmaceuticals Inc is expected to release its next quarterly earnings report in November.
Terns Pharmaceuticals Inc (NASDAQ:TERN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.14% of Terns Pharmaceuticals Inc shares while 84.32% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 84.44%. There are 84.32% institutions holding the Terns Pharmaceuticals Inc stock share, with ORBIMED ADVISORS LLC the top institutional holder. As of 2024-06-30, the company held 10.2326% of the shares, roughly 7.62 million TERN shares worth $51.89 million.
VIVO CAPITAL, LLC holds the second largest percentage of outstanding shares, with 8.3038% or 6.18 million shares worth $42.11 million as of 2024-06-30.
